Replies to post #682149 on NorthWest Biotherapeutics Inc (NWBO)

[Smokey21]

From their site:

“The principle of vaccination with dendritic cells, on which the IO-VAC® is based, has been the focus of intense research interest over several years. The first approved medication of the type is Provenge (Sipuleucel T) against prostate cancer. This, however, does not make use of the patient’s own tumor material, but rather uses preselected antigens. In an advanced stage of clinical trials, a further vaccine (DC-Vax) showed promising results, but has not yet been approved. This vaccine also uses dendritic cells loaded with tumor lysate from the patient. It does, however, not contain an oncolytic virus to increase effectiveness.”